Management of Pulseless Ventricular Tachycardia in Illicit Drug Users
Treat pulseless ventricular tachycardia in drug users identically to any other cardiac arrest: immediate defibrillation is the priority, with standard ACLS protocols taking precedence over any drug-specific considerations. 1
Immediate Management Algorithm
Step 1: Defibrillation First
- Early defibrillation is the definitive treatment and takes absolute priority over pharmacological interventions 1
- Deliver unsynchronized shock at 200 J initially
- If unsuccessful, give second shock at 200-300 J
- If still unsuccessful, deliver third shock at 360 J 2
- Continue high-quality CPR between shocks
Step 2: Establish Vascular Access
- Administer all drugs via intravenous or intraosseous route 1
- Follow peripheral IV drugs with 20 mL saline bolus to ensure central circulation delivery 1
- If no vascular access possible, use endotracheal route with double or triple doses (particularly for epinephrine) 1
Step 3: Pharmacological Management for Refractory VT/VF
Only consider antiarrhythmic drugs after multiple defibrillation attempts fail - specifically when cardioversion does not occur after appropriate advanced life support 1
Drug Options (in order of consideration):
Lidocaine (First-line antiarrhythmic):
- 100 mg IV bolus for cardiac arrest 1
- May repeat after 5-10 minutes 1
- If successful, maintain with 2-4 mg/min infusion 1
- Alternative dosing: 1-3 mg/kg 1
Amiodarone (Alternative/refractory cases):
- 300 mg (5 mg/kg) IV over 15 minutes in cardiac arrest 1
- Can repeat after one hour 1
- Further loading: 15 mg/kg (up to 900 mg) over next 24 hours 1
- Note: Takes up to 30 minutes for antiarrhythmic effect 1
Magnesium (Consider in specific scenarios):
- 8 mmol bolus injection 1
- Particularly effective when VF/VT associated with acute MI 1
- Important caveat: Magnesium is NOT effective for polymorphic VT with normal QT interval 3
Critical Considerations for Drug-Induced Arrhythmias
Stimulant-Specific Pathophysiology
While the immediate management remains standard ACLS, understand that stimulants (cocaine, methamphetamine, MDMA) cause arrhythmias through:
- Direct effects on ion channels and calcium signaling 4
- Massive catecholamine release 5
- Altered cardiac conduction system 4
- Potential unmasking of underlying genetic arrhythmia disorders 5
Common Pitfalls to Avoid
Do NOT delay defibrillation to obtain drug history - the VF protocol is identical regardless of etiology 1
Do NOT use beta-blockers acutely in suspected stimulant overdose with polymorphic VT, as they can precipitate or worsen bradycardia and torsades 3
Do NOT assume the arrhythmia is purely drug-induced - stimulants may unmask underlying catecholaminergic polymorphic VT or other genetic disorders 5
Avoid excessive antiarrhythmic dosing - lidocaine depresses myocardial contractility, and toxic levels cause seizures 1
Post-Resuscitation Considerations
After successful cardioversion:
- Correct electrolyte abnormalities immediately, particularly hypokalemia and hypomagnesemia 3
- Consider coronary intervention if myocardial ischemia suspected (stimulants cause coronary vasospasm) 3
- Maintain lidocaine infusion at 2-4 mg/min if it was effective 1
- Discontinue antiarrhythmic infusions after 6-24 hours and reassess need 2
When Standard Protocol Fails
For truly refractory cases after multiple shocks and standard drugs:
- Bretylium 5 mg/kg diluted in 100 mL dextrose (if unsuccessful, 10 mg/kg) 1
- Continue CPR for at least 20 minutes as bretylium's antiarrhythmic effect is delayed 1
- Expect transient hypertension followed by pronounced hypotension 1
Key Principle
The illicit drug use does not change your immediate management algorithm - pulseless VT is a shockable rhythm requiring immediate defibrillation regardless of cause. Pharmacological treatment is secondary and follows standard ACLS protocols. The drug history becomes relevant for post-resuscitation care, risk stratification, and preventing recurrence, not for the acute cardiac arrest management itself.